USANA Health Sciences, Inc. today announced financial results for its fiscal first quarter ended March 29, 2025. Key Financial Results First Quarter 2025 vs. First Quarter 2024 Net sales of $250 ...

Arcturus Therapeutics Holdings Inc.’s ARCT share price has surged by 6.84%, which has investors questioning if this is right ...

Commercial stage pharmaceutical firm Shield Therapeutics, which has a base in Gateshead, is entering the second quarter of its financial year with "clear momentum", despite the first quarter being ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In a report released yesterday, Lili (Aurélie) Nsongo from Leerink Partners maintained a Hold rating on Arcturus Therapeutics ( ARCT – Research Report ), with a price target of $63.00. Discover ...

1 Day ARCT -2.55% DJIA -1.73% Russell 2K -1.03% Health Care/Life Sciences 0.16% ...

Tvardi Therapeutics, Inc. (Nasdaq: TVRD), a clinical-stage biopharmaceutical company developing novel STAT3 inhibitors for fibrosis-driven diseases, visits the Nasdaq MarketSite in Times Square.

Add a description, image, and links to the arcturus-plugins topic page so that developers can more easily learn about it.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Arcturus Therapeutics Holdings Inc. ARCT announced that the FDA has granted a Fast Track designation to its self-amplifying mRNA (sa-mRNA) vaccine candidate, ARCT-2304, for active immunization to ...